Synergistic combinations of antifungals and anti-virulence agents to fight against Candida albicans

被引：142

作者：

Cui, Jinhui ^{[1
]}

Ren, Biao ^{[1
,2
]}

Tong, Yaojun ^{[1
,3
]}

Dai, Huanqin ^{[1
]}

Zhang, Lixin ^{[1
]}

机构：

[1] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China

[2] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610064, Peoples R China

[3] Tech Univ Denmark, Novo Nordisk Fdn Ctr Biosustainabil, Horsholm, Denmark

来源：

VIRULENCE | 2015年 / 6卷 / 04期

基金：

中国国家自然科学基金;

关键词：

Candida albicans; antifungal drug; drug resistance; virulence factors; synergy; ABC MULTIDRUG TRANSPORTERS; HIV-INFECTED PATIENTS; IN-VITRO INTERACTIONS; AMPHOTERICIN-B; TARGETING VIRULENCE; DRUG-RESISTANCE; INVASIVE CANDIDIASIS; FUNGAL-INFECTIONS; MULTICENTER TRIAL; FLUCONAZOLE;

D O I：

10.1080/21505594.2015.1039885

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Candida albicans, one of the pathogenic Candida species, causes high mortality rate in immunocompromised and high-risk surgical patients. In the last decade, only one new class of antifungal drug echinocandin was applied. The increased therapy failures, such as the one caused by multi-drug resistance, demand innovative strategies for new effective antifungal drugs. Synergistic combinations of antifungals and anti-virulence agents highlight the pragmatic strategy to reduce the development of drug resistant and potentially repurpose known antifungals, which bypass the costly and time-consuming pipeline of new drug development. Anti-virulence and synergistic combination provide new options for antifungal drug discovery by counteracting the difficulty or failure of traditional therapy for fungal infections.

引用

页码：362 / 371

页数：10

共 138 条

[1] A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients [J].